PQRI Workshop: Model-Informed Drug Development (MIDD) Approaches in Pediatric Formulation Development
Gilbert J. Burckart(Center for Drug Evaluation and Research), Andreas Abend(Merck & Co., Inc., Rahway, NJ, USA (United States)), Neil Parrott(Roche (Switzerland)), Daniel González(University of North Carolina at Chapel Hill), Caleb Choi(Center for Drug Evaluation and Research), Susan Abdel-Rahman(Center for Drug Evaluation and Research), Fang Wu(United States Food and Drug Administration), Hardikkumar Patel(United States Food and Drug Administration), Nikoletta Fotaki(University of Bath), David Harris(Merck & Co., Inc., Rahway, NJ, USA (United States)), M. Petrea Cober(Northeast Ohio Medical University), James E. Cummins(National Institutes of Health)
Cited by 0
Related Papers
Clinical Pharmacokinetics of Tacrolimus
|Clinical Pharmacokinetics|1995|802
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
|Journal of Pharmaceutical Sciences|2009|337
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
|Clinical Infectious Diseases|2020|232
Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic
|Obesity|2021|199
Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing
|Clinical Therapeutics|2016|170